FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032545841> ?p ?o ?g. }

• W2032545841 endingPage "363" @default.
• W2032545841 startingPage "357" @default.
• W2032545841 abstract "Gefitinib is an inhibitor of the epidermal growth factor receptor, which is frequently expressed on both choroidal and nonchoroidal melanoma cells. We evaluated the clinical efficacy of gefitinib in patients with metastatic melanoma. Patients with stage IV or unresectable stage III melanoma and Zubrod performance status of less than or equal to 2 were eligible. Previous systemic treatment for metastatic disease was required. The dose of oral gefitinib was 250 mg administered daily, and tumor response was evaluated every 6 weeks. Forty-six patients with nonchoroidal melanoma and six with choroidal melanoma were treated, and 48 were evaluable for response. The median age was 62.5 years. Forty-one patients (79%) had stage M1c disease. There were no drug-related grade 4 or 5 adverse events, and fatigue was the only grade 3 adverse event that occurred in more than 5% of patients. Two patients (4%) had partial responses and 13 patients (27%) had disease stabilization. The two responders had a median duration of response of 10.9 months. The median overall progression-free survival was 1.4 months and the median overall survival was 9.7 months. Among the patients with sufficient tissues obtained before and 6 weeks after starting gefitinib administration, there were no notable trends in the changes of the tumoral expression of p-ERK1/2, p-AKT, PAK1, and serum levels of vascular endothelial growth factor or IL-8 with treatment. We concluded that gefitinib was well tolerated but had minimal clinical efficacy as a single-agent therapy for unselected patients with metastatic melanoma." @default.
• W2032545841 created "2016-06-24" @default.
• W2032545841 creator A5001494021 @default.
• W2032545841 creator A5010742248 @default.
• W2032545841 creator A5015498468 @default.
• W2032545841 creator A5018193013 @default.
• W2032545841 creator A5021527129 @default.
• W2032545841 creator A5027845051 @default.
• W2032545841 creator A5033798832 @default.
• W2032545841 creator A5035218748 @default.
• W2032545841 creator A5035661806 @default.
• W2032545841 creator A5060563693 @default.
• W2032545841 creator A5078841756 @default.
• W2032545841 creator A5081124060 @default.
• W2032545841 creator A5087156478 @default.
• W2032545841 date "2011-08-01" @default.
• W2032545841 modified "2023-10-07" @default.
• W2032545841 title "A phase II study of gefitinib in patients with metastatic melanoma" @default.
• W2032545841 cites W152953340 @default.
• W2032545841 cites W1571264139 @default.
• W2032545841 cites W1989121777 @default.
• W2032545841 cites W2011755139 @default.
• W2032545841 cites W2023764814 @default.
• W2032545841 cites W2027263417 @default.
• W2032545841 cites W2033624161 @default.
• W2032545841 cites W2033758838 @default.
• W2032545841 cites W2034048944 @default.
• W2032545841 cites W2035337464 @default.
• W2032545841 cites W2036128283 @default.
• W2032545841 cites W2043335448 @default.
• W2032545841 cites W2053520756 @default.
• W2032545841 cites W2054016503 @default.
• W2032545841 cites W2056358941 @default.
• W2032545841 cites W2060317877 @default.
• W2032545841 cites W2069357408 @default.
• W2032545841 cites W2106543129 @default.
• W2032545841 cites W2122553809 @default.
• W2032545841 cites W2139248078 @default.
• W2032545841 cites W2140556790 @default.
• W2032545841 cites W2152922289 @default.
• W2032545841 cites W2163188200 @default.
• W2032545841 cites W2166084034 @default.
• W2032545841 cites W2168302736 @default.
• W2032545841 cites W2225834302 @default.
• W2032545841 doi "https://doi.org/10.1097/cmr.0b013e3283471073" @default.
• W2032545841 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3132394" @default.
• W2032545841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21738104" @default.
• W2032545841 hasPublicationYear "2011" @default.
• W2032545841 type Work @default.
• W2032545841 sameAs 2032545841 @default.
• W2032545841 citedByCount "34" @default.
• W2032545841 countsByYear W20325458412012 @default.
• W2032545841 countsByYear W20325458412013 @default.
• W2032545841 countsByYear W20325458412014 @default.
• W2032545841 countsByYear W20325458412015 @default.
• W2032545841 countsByYear W20325458412016 @default.
• W2032545841 countsByYear W20325458412018 @default.
• W2032545841 countsByYear W20325458412019 @default.
• W2032545841 countsByYear W20325458412020 @default.
• W2032545841 countsByYear W20325458412021 @default.
• W2032545841 countsByYear W20325458412022 @default.
• W2032545841 countsByYear W20325458412023 @default.
• W2032545841 crossrefType "journal-article" @default.
• W2032545841 hasAuthorship W2032545841A5001494021 @default.
• W2032545841 hasAuthorship W2032545841A5010742248 @default.
• W2032545841 hasAuthorship W2032545841A5015498468 @default.
• W2032545841 hasAuthorship W2032545841A5018193013 @default.
• W2032545841 hasAuthorship W2032545841A5021527129 @default.
• W2032545841 hasAuthorship W2032545841A5027845051 @default.
• W2032545841 hasAuthorship W2032545841A5033798832 @default.
• W2032545841 hasAuthorship W2032545841A5035218748 @default.
• W2032545841 hasAuthorship W2032545841A5035661806 @default.
• W2032545841 hasAuthorship W2032545841A5060563693 @default.
• W2032545841 hasAuthorship W2032545841A5078841756 @default.
• W2032545841 hasAuthorship W2032545841A5081124060 @default.
• W2032545841 hasAuthorship W2032545841A5087156478 @default.
• W2032545841 hasBestOaLocation W20325458412 @default.
• W2032545841 hasConcept C121608353 @default.
• W2032545841 hasConcept C126322002 @default.
• W2032545841 hasConcept C143998085 @default.
• W2032545841 hasConcept C146357865 @default.
• W2032545841 hasConcept C151730666 @default.
• W2032545841 hasConcept C197934379 @default.
• W2032545841 hasConcept C2776694085 @default.
• W2032545841 hasConcept C2777658100 @default.
• W2032545841 hasConcept C2778822529 @default.
• W2032545841 hasConcept C2779438470 @default.
• W2032545841 hasConcept C2780580887 @default.
• W2032545841 hasConcept C31760486 @default.
• W2032545841 hasConcept C502942594 @default.
• W2032545841 hasConcept C71924100 @default.
• W2032545841 hasConcept C86803240 @default.
• W2032545841 hasConcept C90924648 @default.
• W2032545841 hasConceptScore W2032545841C121608353 @default.
• W2032545841 hasConceptScore W2032545841C126322002 @default.
• W2032545841 hasConceptScore W2032545841C143998085 @default.
• W2032545841 hasConceptScore W2032545841C146357865 @default.
• W2032545841 hasConceptScore W2032545841C151730666 @default.

• next